ArticleInfectious agents and cancer2025
Clinical characteristics and prognostic impact of HPV infection in head and neck cancer patients in china: a nationwide multicenter study.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prognostic Implications of p16 Immunohistochemistry and Its Discordance with Transcriptionally Active HPV in Oropharyngeal Squamous Cell Carcinoma: A Taiwanese Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Clinical characteristics, treatment patterns, and prognosis in vulvar cancer and vaginal cancer: a national multicenter retrospective study in China.BMC public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundHuman papillomavirus (HPV) has emerged as a major cause of head and neck cancer (HNC), yet nationwide HPV-stratified disease data are still lacking in China. The literature remains divided on the prognostic impact of HPV infection.
methodsThe HNC patients treated from 1 January 2017 to 30 June 2021 were retrospectively identified at nine tertiary A centers representing the seven geographic regions of China. Event-free survival (EFS) and cancer-specific survival (CSS) were estimated with the Kaplan-Meier method and compared using the log-rank test. Early survival differences by subsite and HPV status were assessed using restricted mean survival time differences for EFS (ΔRMEFST) and CSS (ΔRMCSST), adjusting for confounders with pseudo-value regression.
resultsThe study included 345 cases. Most of the Chinese HNC patients in this study were male (84.64%), and more than one-third were already at clinical Tumor-Node-Metastasis (cTNM) stage IV at diagnosis. Among the 237 patients who underwent HPV testing, 18.99% were HPV-positive, with the highest prevalence in oropharyngeal cancers (37.29%) and the lowest in laryngeal cancers (7.48%; p < 0.001). A higher proportion of HPV‑positive patients consumed alcohol (44.44%), received radiotherapy (53.33%) and chemotherapy (88.89%), whereas a lower proportion underwent surgery (62.22%) (all p < 0.001). In oral cancer, EFS was higher in the HPV-positive group (log-rank p = 0.002); after adjustment for confounders, the 12-month ΔRMEFST was 1.576 months (95%CI = 0.157, 2.996; p = 0.029). Among patients with oropharyngeal cancer, both EFS and CSS were higher in the HPV-positive group than in the HPV-negative group (all log-rank p < 0.050). After multivariable adjustment, the 12-month ΔRMCSST was 0.629 months (95%CI = 0.019, 1.238; p = 0.043). Laryngeal cancer patients showed no HPV-related differences in EFS or CSS (all p > 0.050). A 24-month landmark sensitivity analysis confirmed the survival advantage in oral and oropharyngeal cancer.
conclusionsDemographics, risk profiles, presentation, and treatment patterns differ sharply by HPV status. Early survival is better for HPV-positive oral and oropharyngeal cancers but not for laryngeal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.